Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil is patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Pricing for Ultiva. 1 mg vial - 30.19 USD; 3 mg vial - 57.20 USD; 5 mg vial - 118.15 USD
Breach of contract is a legal cause of action in which a binding agreement or bargained-for exchange is not honored by one or more of the parties to the contract by non-performance or interference with the other party's performance.
In most cases of breach, a party to the contract simply fails to perform one or more terms. In those cases, the breaching party should have already considered the cost to perform those terms and thus keeps that cost when they do not perform. That party should not be entitled to keep that savings.